The report covers emerging Scleroderma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Scleroderma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Scleroderma: An Overview
Scleroderma is a connective tissue disorder characterized primarily by the thickening and hardening of the skin. The combining form “sclero” means “hard” in Greek, and the word “dermis” means skin. There are two primary types of scleroderma: localized and systemic (also called systemic sclerosis). In localized scleroderma, the disease affects mainly the skin and may have an impact on the muscles and bones. In systemic scleroderma, there is an involvement of the internal organs, such as the digestive tract, heart, lungs, and kidneys, among others. The severity and outcome of scleroderma are variable.
As scleroderma tends to have many symptoms, a combination approach might often be required for the treatment and management of symptoms in an effective manner. For localized forms of scleroderma, topical medications are often found to be beneficial. Moisturizers can be used for the prevention of the skin from drying out as well as for the treatment of the hardened skin. For improving upon the blood flow, so that the sores within the fingers can heal, nitrates like nitroglycerin are prescribed. The nitrates function by relaxing the smooth muscles, causing dilation of the arteries.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Scleroderma pipeline therapies. It also thoroughly assesses the Scleroderma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Scleroderma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Scleroderma Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Scleroderma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Scleroderma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
Scleroderma Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Scleroderma market or expected to be launched during the study period. The analysis covers the Scleroderma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Scleroderma drugs based on their sale and market share.
The report also covers the Scleroderma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Scleroderma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Scleroderma Market Will Evolve and Grow by 2032 @
Scleroderma Therapeutics Analysis
For patients suffering from scleroderma and who have been undergoing worsening pulmonary fibrosis, also called scarring of the lung, the drug cyclophosphamide (Cytoxan), has been found to be useful. For patients dealing with pulmonary hypertension, the most successful form of treatment is the continuous intravenous infusion of epoprostenol (Flolan), a prostaglandin, through a pump.
Subcutaneous infusion of treprostinil (Remodulin) – a related prostaglandin, is a permitted alternative. Prostaglandins are hormone-like substances that can be found in the body, among various other things, helping in relaxing the smooth muscles and thereby dilating the blood vessels.
The other forms of therapy that are currently FDA-approved for the treatment of pulmonary hypertension involve oral bosentan (Tracleer), sildenafil (Revatio), and inhaled iloprost (Ventavis).
Several major pharma and biotech companies are developing therapies for Scleroderma. Currently, Certa Therapeutics is leading the therapeutics market with its Scleroderma drug candidates in the most advanced stage of clinical development.
Scleroderma Companies Actively Working in the Therapeutics Market Include
Emerald Health Pharmaceuticals
Maruho Co., Ltd.
Mitsubishi Tanabe Pharma
And Many Others
Emerging and Marketed Scleroderma Therapies Covered in the Report Include:
FT011: Certa Therapeutics
EHP 101: Emerald Health Pharmaceuticals
ACE-1334: Acceleron Pharma
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Scleroderma Competitive Intelligence Analysis
4. Scleroderma Market Overview at a Glance
5. Scleroderma Disease Background and Overview
6. Scleroderma Patient Journey
7. Scleroderma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Scleroderma Treatment Algorithm, Current Treatment, and Medical Practices
9. Scleroderma Unmet Needs
10. Key Endpoints of Scleroderma Treatment
11. Scleroderma Marketed Therapies
12. Scleroderma Emerging Drugs and Latest Therapeutic Advances
13. Scleroderma Seven Major Market Analysis
14. Attribute Analysis
15. Scleroderma Market Outlook (In US, EU5, and Japan)
16. Scleroderma Companies Active in the Market
17. Scleroderma Access and Reimbursement Overview
18. KOL Views on the Scleroderma Market
19. Scleroderma Market Drivers
20. Scleroderma Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Exocrine Pancreatic Insufficiency Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Exocrine Pancreatic Insufficiency market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States